CSIR’s anti-cancer drug IIIM-290 went into clinical trial
CSIR constituent lab, CSIR-Indian Institute of Integrative Medicine (IIIM) Jammu, has received Investigational New Drug (IND) approval from New Drugs Division of Central Drugs Standard Control Organisation (CDSCO) for a potent anti-cancer, new chemical entity (NCE) effective against pancreatic cancer after successful completion of preclinical development and IND submission. The proposed clinical trial will pave […]
CSIR’s anti-cancer drug IIIM-290 went into clinical trial Read More »










